ArticleJournal of gastroenterology and hepatology2026
Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort.
Article in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Commentary on "Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort".Journal of gastroenterology and hepatology · 2026Article
- Defining Disabling Disease in Moderate-to-Severe Ulcerative Colitis: Beyond Treatment Escalation.Journal of gastroenterology and hepatology · 2026Article
- From Disease Trajectories to Treatment Decisions in Ulcerative Colitis: Treatment-Aware Validation Is Needed.Journal of gastroenterology and hepatology · 2026Article
- Comment on "Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort".Journal of gastroenterology and hepatology · 2026Article
- Letter to the Editor: 5-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort.Journal of gastroenterology and hepatology · 2026Article
- Beyond Colectomy-Interpreting Long-Term Disease Burden and Clinical Trajectories in Moderate-to-Severe Ulcerative Colitis.Journal of gastroenterology and hepatology · 2026Article
- Commentary on "Five-Year Outcomes and Disease Trajectories in Moderate-to-Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort".Journal of gastroenterology and hepatology · 2026Article
- Clarifying Composite Outcomes and Baseline Prognostic Analysis in Ulcerative Colitis.Journal of gastroenterology and hepatology · 2026Article
- Methodological Considerations in Defining Disabling Disease Trajectories in Moderate-to-Severe Ulcerative Colitis.Journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
BACKGROUND AND
aimThe incidence of ulcerative colitis (UC) has been increasing in Asia. Comprehensive data on the long-term course of moderate-to-severe UC remain scarce. This study investigated the clinical outcomes and factors associated with a disabling disease course in Korean patients with moderate-to-severe UC.
methodsThe moderate-to-severe ulcerative colitis in Korea study was a prospective, multicenter, hospital-based inception cohort study that enrolled patients with newly diagnosed moderate-to-severe UC between August 2014 and February 2017. Clinical outcomes and factors associated with a disabling disease course were evaluated over 5 years.
resultsAmong 353 patients included, the median follow-up duration was 4.9 (interquartile range, 2.1-5.0) years, and 214 patients (60.6%) completed the 5-year follow-up. At 5 years, the cumulative rates of outcomes were clinical relapses, 62.9%; proximal disease extension, 29.5%; and UC-related hospitalization, 22.4%. Colectomy was required in two patients (0.6%), without mortality. A disabling disease course occurred in 171 patients (48.4%), with cumulative probabilities of 41.0%, 51.1%, and 53.9% at 12, 36, and 60 months, respectively. Elevated baseline white blood cell count was independently associated with a disabling disease course (adjusted hazard ratio: 1.06; 95% confidence interval: 1.00-1.12; p = 0.035). Five distinct partial Mayo score-based disease trajectory clusters were identified, demonstrating clear prognostic separation.
conclusionsWhile Korean patients with moderate-to-severe UC showed a benign structural disease course with minimal colectomy rates, approximately half experienced a disabling disease course. The identified disease trajectories provide a novel framework for risk stratification and personalized management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.